- AZD-5438
-
- $44.00 / 5mg
-
2025-09-24
- CAS:602306-29-6
- Min. Order:
- Purity: 99.23%
- Supply Ability: 10g
- AZD-5438；AZD5438
-
- $0.00 / 1g
-
2025-08-21
- CAS:602306-29-6
- Min. Order: 10g
- Purity: 99.0%min. HPLC
- Supply Ability: 1000kg
- AZD 5438
-
- $9.80 / 1.79999995231628KG
-
2019-12-26
- CAS:602306-29-6
- Min. Order: 1g
- Purity: ≥99%
- Supply Ability: 100kg
|
| | AZD 5438 Basic information |
| Product Name: | AZD 5438 | | Synonyms: | 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-;AZD 5438;4-[2-Methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine;AZD;4-[2-Methyl-1-(1-Methylethyl)-1H-iMidazol-5-yl]-N-[4-(Methylsulfonyl)phenyl]-;2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-(AZD 5438);4-[2-Methyl-1-isopropyl-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine;4-[2-Methyl-1-isopropyl-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine AZD 5438 | | CAS: | 602306-29-6 | | MF: | C18H21N5O2S | | MW: | 371.46 | | EINECS: | | | Product Categories: | Inhibitors;API intermediates;Potent inhibitor of cyclin-dependent kinase (cdk) 1, 2 and 9. | | Mol File: | 602306-29-6.mol |  |
| | AZD 5438 Chemical Properties |
| Boiling point | 655.2±65.0 °C(Predicted) | | density | 1.31 | | storage temp. | Keep in dark place,Inert atmosphere,2-8°C | | solubility | insoluble in H2O; ≥18.55 mg/mL in DMSO; ≥42.1 mg/mL in EtOH | | form | solid | | pka | 4.08±0.50(Predicted) | | color | White to light yellow | | InChI | InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22) | | InChIKey | WJRRGYBTGDJBFX-UHFFFAOYSA-N | | SMILES | C1(NC2=CC=C(S(C)(=O)=O)C=C2)=NC=CC(C2N(C(C)C)C(C)=NC=2)=N1 |
| | AZD 5438 Usage And Synthesis |
| Uses | AZD 5438 is a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, which leads to leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. | | Definition | ChEBI: 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine is a sulfonamide. | | Biological Activity | azd5438 is a potent small molecule inhibitor of cyclin-dependent kinase (cdk) 1, 2 and 9 with half maximal inhibitory concentration ic50 of 16 nmol/l, 6 nmol/l and 20 nmol/l respectively. azd5438 has also been found to potently inhibit the human cyclin e/cdk2 complex, the cyclin b1/cdk1 complex and the cyclin a/cdk2 complex with ic50 of 0.006 μm, 0.016 μm and 0.045 μm respectively. in previous studies, azd5438 has exhibited significant anti-proliferative activity in a few human tumor cell lines with ic50 ranging from 0.2 μmol/l to 1.7 μmol/l, in which the phosphorylation of a few proteins, including cdk substrates prb, nucleolin, protein phosphatase 1a and rna polymerase ii cooh-terminal domain, and cell cycling at g2-m, s and g1 phases were inhibited. | | in vivo | AZD5438 (50 mg/kg twice daily or 75 mg/kg, p.o.) inhibits human tumor xenograft growth. In vivo, AZD5438 reduces the proportion of actively cycling cells. Further pharmacodynamic analysis of AZD5438-treated SW620 xenografts shows that efficacious doses of AZD5438 (>40% tumor growth inhibition) maintains suppression of biomarkers, such as phospho-pRbSer249/Thr252, for up to 16 hours following a single oral dose[1]. | | IC 50 | cdk2-cyclin E: 6 nM (IC50); cdk2-cyclin A: 45 nM (IC50); cdk5-p25: 14 nM (IC50); cdk1-cyclin B1: 16 nM (IC50); cdk9-cyclin T: 20 nM (IC50); cdk6-cyclin D3: 21 nM (IC50); cdk4-cyclin D1: 449 nM (IC50); cdk7-cyclin H: 821 nM (IC50) | | storage | Desiccate at RT | | references | [1]camidge dr1, smethurst d, growcott j, barrass nc, foster jr, febbraro s, swaisland h, hughes a. a first-in-man phase i tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor azd5438 in healthy male volunteers. cancer chemother pharmacol. 2007 aug;60(3):391-8. epub 2006 nov 18.
[2]byth kf, thomas a, hughes g, forder c, mcgregor a, geh c, oakes s, green c, walker m, newcombe n, green s, growcott j, barker a, wilkinson rw. azd5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. mol cancer ther. 2009 jul;8(7):1856-66. doi: 10.1158/1535-7163.mct-08-0836. epub 2009 jun 9. |
| | AZD 5438 Preparation Products And Raw materials |
|